41964-07-2

Basic information

• Product Name: Tolimidone
• Synonyms: Tolimidone;5-(m-Tolyloxy)pyrimidin-2(1H)-one;CP-26154;2(1H)-Pyrimidinone, 5-(3-methylphenoxy)-;5-(3-methylphenoxy)-1H-pyrimidin-2-one;5-(3-Methylphenoxy)-2(1H)-pyrimidinone;NSC 314335;MLR 1023
• CAS NO: 41964-07-2
• Molecular Formula: C₁₁H₁₀N₂O₂
• Molecular Weight: 202.212
• EINECS: 200-258-5
• Mol File: 41964-07-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 163-164℃
• Appearance: white to beige/
• Density: 1.22
• Refractive Index: 1.598
• Storage Temp.: room temp
• Solubility: DMSO: soluble15mg/mL (clear solution)
• CAS DataBase Reference: Tolimidone(CAS DataBase Reference)
• NIST Chemistry Reference: Tolimidone(41964-07-2)
• EPA Substance Registry System: Tolimidone(41964-07-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 41964-07-2(Hazardous Substances Data)

Usage

Description

Tolimidone, also known as MLR-1023, is an allosteric activator of Lyn kinase with an EC50 of 63 nM. It is a promising pharmaceutical candidate with no significant activity against a panel of related kinases. Tolimidone is orally bioavailable and has been shown to reduce blood glucose levels in mice, particularly in an insulin-dependent manner, by increasing insulin receptor sensitivity. Tolimidone produces a dose-dependent and durable glucose-lowering effect in chronically treated db/db mice without causing weight gain.

Uses

Used in Pharmaceutical Industry:
Tolimidone is used as an insulin receptor-potentiating agent for its ability to reduce blood glucose levels in mice. It has been shown to be effective in increasing insulin receptor sensitivity, which makes it a potential candidate for the treatment of type 2 diabetes.
Used in Diabetes Treatment:
Tolimidone is used as a glucose-lowering agent for its durable and dose-dependent effect in reducing blood glucose levels. It has the potential to be a valuable treatment option for diabetic patients, as it can help manage blood glucose levels without causing weight gain.

InChI:InChI=1/C11H10N2O2/c1-8-3-2-4-9(5-8)15-10-6-12-11(14)13-7-10/h2-7H,1H3,(H,12,13,14)

Upstream product

• 108-39-4 3-methyl-phenol 
• 58042-45-8 3-methylphenoxyacetaldehyde diethyl acetal 
• 57-13-6 urea 
• 53341-46-1 (E)-3-(dimethylamino)-2-(meta-tolyloxy)acrylaldehyde 

Relevant articles and documents

METHOD FOR PREPARING TOLIMIDONE ON LARGE SCALE

The present disclosure relates to a method for preparing tolimidone on large scale with maintaining high purity and uniform particle size distribution, and more specifically, a method suitable for preparing tolimidone on industrially large scale by using

Bronchodilator and Antiulcer Phenoxypyrimidinones

Series of 5-phenoxy-2(1H)-pyrimidinones, 5-phenoxy-4(3H)-pyrimidinones, and related compounds were prepared in a follow-up of a lead prepared as a potential cyclic nucleotide regulating agent.Compounds were evaluated for bronchodilator activity in histamine-challenged guinea pigs and for antiulcer activity in a cold-restraint, stressed rat ulcer model.Bronchodilator activity comparable to, or greater than, that of theophylline was found in both the 2(1H)- and 4(3H)-pyrimidinone series and was most prominent in analogues containing either an electron-withdrawing or -donating substituent in the para position of the phenoxy ring.Significant antiulcer activity was observed only in the 2(1H)-pyrimidinone series among three closely related analogues.One of these, 5-(m-methylphenoxy)-2(1H)-pyrimidinone (3), exhibited more potent antiulcer effects than the clinically useful antiulcer agent carbenoxolone, without demonstrating bronchodilator activity.